About Ophthalmic Therapeutic Innovation

 OTI-2024 was previously developed by Inotek Pharmaceuticals (known as trabodenoson or INO-8775) in Massachusetts. It completed four randomized control clinical trials in about 800 patients with glaucoma (2009–2017), demonstrating its excellent clinical safety and MMP therapeutic potency (not recognized by Inotek Pharma). However, it failed in a prior Phase 3 IOP reduction clinical trial due to an incorrect dose and misunderstanding of its unique dual-action mechanism (IOP + Neuro/MMP). [Ref: https://pubmed.ncbi.nlm.nih.gov/33405971/]

In June 2022, Dr. Tina Qiu made new discoveries of trabodenoson-derived MMP therapeutic leading to a disease free IOP drug holiday (connecting dots from Durysta /MMP therapeutic benefits to patients), and for treating refractory glaucoma and glaucomatous neural degeneration via IOP normalization. In Oct 2023, Dr Qiu nailded down the rate limiting diseaase root cause of glaucoma with which OTI-2024/MMP became the first curative therapy. She spent 18 months under stealth mode, patenting her inventions, before founding Ophthalmic Therapeutic Innovation LLC (OTI) in November 2023.

Ownership of New IPs and New IND Data (100% with OTI): No upfront and no royalty obligation.